hotspot -WSS

hotspot

author：leisure time 2025-09-30 13:44:20 - browse：815

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： What a koala virus tells us about the human genome

WSS

How to keep neuroscience’s past racism from being its future

How to keep neuroscience’s past racism from being its future

In Spain, a hospital brews its own CAR

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

hotspot

hotspot

leisure time

Cancer drug shortages should be causing more outrage

Virtual care provider acquires bankrupt Pear's prescription apps

Trump demands the U.S. pay no more for drugs than other countries … again

What a koala virus tells us about the human genome

State Dept. review finds Biden bears some blame for Afghanistan failures

Why health records don't always know when patients are dead

Hepatitis C has a cure — but many Americans still lack access to it

Supreme Court to hear if Covid misinformation is protected speech

How one medical school became remarkably diverse

CRISPR gene editing developments we’re watching in 2024

focus

Hospitals owned by private equity see complications spike 25%

STAT reporters are Pulitzer Prize finalists for investigative reporting

Editas, Vertex strike deal on CRISPR

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Keeping primary care docs in field isn't impossible, says AAFP CEO

knowledge

focus

hotspot

entertainment